Genome Canada

Marc LePage, president and CEO of Genome Canada describes the early days of the organization and talks modern day plans, such as personalized diagnostics for rare diseases, international alliances and…

Save Share

OtoSim’s CEO Andy Sinclair discusses the current issues surrounding otoscopy diagnosis and the potential of the company’s groundbreaking simulation technology. What was your motivation for getting involved with OtoSim Inc.…

Save Share

The CEO of OBIO discusses Ontario’s challenges and opportunities in life sciences, highlighting some of the key initiatives that the organization is taking to help local companies bridge the gap…

Save Share

Jim Keon, Preisdent of CGPA, discusses the cost-saving benefits that generic drugs have offered Canada, and offers his insights into Canada’s intellectual property regime and the challenges of pricing in…

Save Share

Warren Shapiro, manager of the North American division of Brunel’s life science sector, offers his insights into Canada’s immense human resources capabilities as well as Brunel’s footprint for contract labor…

Save Share

  Mario Piccinin and Lara Iob of EY Canada discuss some of the key trends of the country’s biotech industry and the affiliate’s dedication to helping clients navigate the SR&ED…

Save Share

President of Biotalent Canada discusses the advantages of being wholly aligned with the government, why the BioTalent is a necessary link between talent and company, and what this means for…

Save Share

The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…

Save Share

Prior to joining Life Sciences Ontario (LSO), you served as CEO of GSK Canada for a number of years. What opportunities did you see in making the switch from an…

Save Share

The president of Sanofi Pasteur Canada discusses the greatest challenges currently facing vaccine companies in Canada, and the added value that Canada’s R&D framework brings to a vaccine company like…

Save Share

The president & CEO of Canada’s largest generics player considers the current market dynamics for generic products, including IP regulation, generic penetration, and the advantages of balancing branded and non-branded…

Save Share

The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government…

Save Share

The head of Lundbeck in Canada talks about the stigma of mental illness that still exists in the country today, and how CNS companies like Lundbeck are working with stakeholders…

Save Share